Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Texas Neurology

Neither a doctor nor a teaching hospital

Research payments

$311,389

90 payments

Through program year 2025, Texas Neurology is reported as receiving $311,389 in research payments, across 90 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $53,691 38
2024 Research $4,796 5
2023 Research $116,600 8
2022 Research $48,651 12
2021 Research $6,246 4
2020 Research $25,337 9
2019 Research $56,067 14

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $90,303 10 payments
  2. Ipsen Innovation $48,037 39 payments
  3. Alexion Pharmaceuticals, Inc. $42,761 4 payments
  4. Orion Corporation $42,391 9 payments
  5. Biohaven Pharmaceutical Holding Company Ltd. $38,316 6 payments
  6. Mallinckrodt Enterprises LLC $13,233 5 payments
  7. Amylyx Pharmaceuticals, Inc. $12,573 2 payments
  8. Allergan Inc. $11,850 4 payments
  9. AbbVie, Inc. $4,025 5 payments
  10. Avanir Pharmaceuticals, Inc. $4,000 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed By Extended Treatment With Open-Label Remibrutinib $70,121 3 payments
  2. Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS $42,391 9 payments
  3. Healey Platform Trial $38,316 6 payments
  4. A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants $32,451 25 payments
  5. Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement Inhibitor Naive Adult Patients With Generalized Myasthenia Gravis $21,661 1 payment
  6. Long Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies $21,100 3 payments
  7. A 12 Months Prospective, Interventional, Multinational, Open-Label, Active-Controlled Study Comparing Sustained Benefit of Two Treatment Paradigms (Erenumab 140 MG QM VS Oral Prophylactics) $17,140 4 payments
  8. Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants $15,586 14 payments
  9. A Double Blind, Placebo Controlled Study of H.P. Acthar Gel in the Management of Amyotrophic Lateral Sclerosis $14,483 6 payments
  10. Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment (Phoenix) $12,573 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record